Bio-Rad Laboratories
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.About BIO.B
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments.
CEONorman D. Schwartz
CEONorman D. Schwartz
Employees7,700
Employees7,700
HeadquartersHercules, California
HeadquartersHercules, California
Founded1952
Founded1952
Employees7,700
Employees7,700
BIO.B Key Statistics
Market cap8.38B
Market cap8.38B
Price-Earnings ratio-12.78
Price-Earnings ratio-12.78
Dividend yield—
Dividend yield—
Average volume31.44
Average volume31.44
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$359.22
52 Week high$359.22
52 Week low$225.29
52 Week low$225.29
Stock Snapshot
As of today, Bio-Rad Laboratories(BIO.B) shares are valued at $310.70. The company's market cap stands at 8.38B, with a P/E ratio of -12.78.
On 2025-12-06, Bio-Rad Laboratories(BIO.B) stock opened at —, reached a high of —, and a low of —.
The Bio-Rad Laboratories(BIO.B)'s current trading volume is 0, compared to an average daily volume of 31.44.
During the past year, Bio-Rad Laboratories(BIO.B) stock moved between $225.29 at its lowest and $359.22 at its peak.
During the past year, Bio-Rad Laboratories(BIO.B) stock moved between $225.29 at its lowest and $359.22 at its peak.
BIO.B News
Simply Wall St 7d
Does Bio-Rad’s Expanded StarBright Dye Line Shift the Innovation Narrative for BIO?Earlier this week, Bio-Rad Laboratories announced the expansion of its StarBright Dye series for flow cytometry, adding four new dyes with unique spectral profi...
Analyst ratings
57%
of 7 ratingsBuy
42.9%
Hold
57.1%
Sell
0%
People also own
Based on the portfolios of people who own BIO.B. This list is generated using Robinhood data, and it’s not a recommendation.